Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8443551 | European Journal of Cancer | 2014 | 11 Pages |
Abstract
A survival advantage for MMT persisted long-term in AC and was replicated in SCC. MMT produced loco-regional tumour down-staging to extinction in 25-31% of patients, potentially permitting personalised treatment in this cohort that avoids the morbidity and mortality associated with resection. Node-negative patients with residual localised disease following MMT had a survival advantage over node-negative patients following surgery alone, supporting a systemic effect on micro-metastatic disease.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
G.A. Bass, H. Furlong, K.E. O'Sullivan, T.P.J. Hennessy, T.N. Walsh,